CN101732236A - Solid medicine preparation for preventing agglomeration and discoloration and preparation method thereof - Google Patents
Solid medicine preparation for preventing agglomeration and discoloration and preparation method thereof Download PDFInfo
- Publication number
- CN101732236A CN101732236A CN201010030160A CN201010030160A CN101732236A CN 101732236 A CN101732236 A CN 101732236A CN 201010030160 A CN201010030160 A CN 201010030160A CN 201010030160 A CN201010030160 A CN 201010030160A CN 101732236 A CN101732236 A CN 101732236A
- Authority
- CN
- China
- Prior art keywords
- sodium
- preparation
- solid pharmaceutical
- pharmaceutical preparation
- stabilizing agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a solid medicine preparation for preventing agglomeration and discoloration and a preparation method thereof. The solid medicine preparation contains 5-30g of active component of a chemical medicine, 0.1-0.3g of stabilizing agent, 1-10g of silicon dioxide and 59.7-93.9g of carrier. The active component of the chemical medicine is firstly mixed with stabilizing agent and silicon dioxide evenly and then is mixed with the carrier evenly. The medicine preparation is not easy to discolor and agglomerate in the processes of preservation and use and has extensive material selection, extensive application range and simple preparation process.
Description
Technical field
The invention belongs to the veterinary drug formulation art, be specifically related to a kind of solid pharmaceutical preparation prescription of variable color and preparation method thereof that lumps that prevents.
Background technology
Solid pharmaceutical preparation is the variable color caking in the preservation process, it is the ubiquitous problem of veterinary drug preparation, in order to address this is that, China's researcher has adopted many methods: as (test and research [J] the Hebei animal and veterinaries 2003 of change gentamycin sulfate soluble powder pharmaceutical formulation such as Li Hongxing, 19 (3): 25) adopt the method for changing soluble starch control moisture to prevent to change the caking variable color, the shortcoming of this method is that the scope of application is narrow, the molten water of soluble starch is poor in addition, become bulk in water easily, influence is used.
Summary of the invention
The technical problem to be solved in the present invention provides a kind of solid pharmaceutical preparation of the variable color that prevents to lump.This solid pharmaceutical preparation prescription selection is extensive, effective, applied widely.
Another technical problem that the present invention will solve provides a kind of preparation method of this solid pharmaceutical preparation.This method technology is simple.
The solid pharmaceutical preparation prescription of prevention caking provided by the invention variable color comprises following composition:
Chemicals active component 5～30g
Stabilizing agent 0.1～0.3g
Silica 1～10g
Carrier 59.7～93.9g
Chemicals active component of the present invention comprises amoxicillin, sulfadiazine sodium, sulfameter sodium, sulfamonomethoxine sodium, sulfadimidine sodium, ciprofloxacin lactate, ciprofloxacin, hydrochloric acid sarafloxacin, tylosin tartrate, doxycycline hydrochloride, polygynax or gentamycin sulfate etc.
Stabilizing agent of the present invention comprises sodium dihydrogen phosphate, potassium dihydrogen phosphate, sodium hydrogen phosphate or sodium phosphate.
Silicon dioxide particle diameter used in the present invention is generally 0.1 μ m-10 μ m.
Carrier of the present invention is anhydrous glucose or cane sugar powder.
Solid pharmaceutical preparation of the present invention can be by following preparation method: the chemicals active component earlier with stabilizing agent and silicon dioxide mix homogeneously, and then with the carrier mix homogeneously.
Solid pharmaceutical preparation prevented from caking provided by the invention and variable color, and silicon dioxide and stabilizing agent is cheap and easy to get, consumption is few; Preparation method is simple, is fit to suitability for industrialized production.
The specific embodiment
Embodiment 1
Get amoxicillin 5g and silica 1 g, sodium dihydrogen phosphate 0.1g, mix homogeneously adds anhydrous glucose 59.7g then, and mixing gets amoxicillin soluble powder.Batch number is: 20080501
Embodiment 2
Get amoxicillin 30g and silica 1 0g, sodium dihydrogen phosphate 0.3g, mix homogeneously adds anhydrous glucose 93.9g then, mixing, promptly.
Embodiment 3
Get amoxicillin 18g and silicon dioxide 5g, sodium dihydrogen phosphate 0.2g, mix homogeneously adds anhydrous glucose 79.7g then, mixing, promptly.
Embodiment 4
Get amoxicillin 5g and silica 1 0g, sodium dihydrogen phosphate 0.3g, mix homogeneously adds anhydrous glucose 93.9g then, mixing, promptly.
Embodiment 5
Get amoxicillin 30g and silica 1 g, sodium dihydrogen phosphate 0.1g, mix homogeneously adds anhydrous glucose 59.7g then, mixing, promptly.
Comparative Examples 1
Get amoxicillin 10g, add anhydrous glucose 90g, mixing gets amoxicillin soluble powder.Batch number is: 20080502.
Embodiment 6 stability tests
According to " chemicals stability test guideline " amoxicillin soluble powder is carried out high humidity influence factor test.
Experimental condition
Test specimen: batch number is 20080501 amoxicillin soluble powder.
Batch number is 20080502 amoxicillin soluble powder.
Test apparatus: the rich news in SPX-250IC micro computer growth cabinet Shanghai Medical Equipment Plant.
Investigation project: character, discriminating, moisture absorption weightening finish, content etc.
Judging standard: by 2003 version The Ministry of Agriculture of the People's Republic of China, MOA " veterinary drug quality standard " differentiate.
Test site: Henan Province's veterinary drug Engineering Technical Research Centre.
Process of the test: with test specimen respectively diameter be the weighing botle of 50mm, spread out into the thick thin layer of 5mm, place 25 ℃ of temperature, the SPX-250IC micro computer growth cabinet of relative humidity 90% ± 5% was placed 10 days, in the 5th day and sampling in the 10th day, observe determination test result such as table 1.
Table 1 amoxicillin soluble powder high humidity influence factor result of the test
Result of the test shows, adds the amoxicillin soluble powder of silicon dioxide and stabilizing agent, places 10 days under 25 ℃, relative humidity (RH) 90% ± 5% condition, and color and character do not change, and the suction weightening finish is 3.7%, and content is no change almost; And the sample placement that does not add stabilizing agent and silicon dioxide 5 days was the variable color caking, and placing suction weightening finish in 10 days is 5.1%, and content has reduced by 12.3%.
Claims (4)
1. the solid pharmaceutical preparation of the variable color that prevents to lump comprises following composition:
Chemicals active component 5～30g
Stabilizing agent 0.1～0.3g
Silica 1～10g
Carrier 59.7～93.9g.
2. the solid pharmaceutical preparation of prevention caking according to claim 1 variable color is characterized in that the chemicals active component is meant amoxicillin, sulfadiazine sodium, sulfameter sodium, sulfamonomethoxine sodium, sulfadimidine sodium, ciprofloxacin lactate, ciprofloxacin, hydrochloric acid sarafloxacin, tylosin tartrate, doxycycline hydrochloride, polygynax or gentamycin sulfate; Stabilizing agent is meant sodium dihydrogen phosphate, potassium dihydrogen phosphate, sodium hydrogen phosphate or sodium phosphate; Described carrier is anhydrous glucose or cane sugar powder.
3. the solid pharmaceutical preparation of prevention caking according to claim 1 and 2 variable color is characterized in that described silicon dioxide particle diameter is 0.1 μ m-10 μ m.
4. the preparation method of the solid pharmaceutical preparation of claim 1 or 2 described preventions caking variable colors, chemicals active component earlier with stabilizing agent and silicon dioxide mix homogeneously, and then with the carrier mix homogeneously.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010030160A CN101732236A (en) | 2010-01-13 | 2010-01-13 | Solid medicine preparation for preventing agglomeration and discoloration and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010030160A CN101732236A (en) | 2010-01-13 | 2010-01-13 | Solid medicine preparation for preventing agglomeration and discoloration and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101732236A true CN101732236A (en) | 2010-06-16 |
Family
ID=42456609
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201010030160A Pending CN101732236A (en) | 2010-01-13 | 2010-01-13 | Solid medicine preparation for preventing agglomeration and discoloration and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101732236A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105919941A (en) * | 2016-05-17 | 2016-09-07 | 湖南泰谷生物兽药有限公司 | Composition containing amoxicillin and potassium clavulanate, and preparation method thereof |
| CN106366143A (en) * | 2016-08-30 | 2017-02-01 | 河北舒凯生物科技有限公司 | Tylosin lactate compounds, and composition and application thereof |
| CN106509372A (en) * | 2016-10-09 | 2017-03-22 | 杨松杞 | New water-soluble carrier and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101234119A (en) * | 2008-03-11 | 2008-08-06 | 四川大学 | Compound soluble powder for preventing and controlling pig intestinal bacterial disease |
-
2010
- 2010-01-13 CN CN201010030160A patent/CN101732236A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101234119A (en) * | 2008-03-11 | 2008-08-06 | 四川大学 | Compound soluble powder for preventing and controlling pig intestinal bacterial disease |
Non-Patent Citations (2)
| Title |
|---|
| 王齐放等: ""pH及不同缓冲盐对阿莫西林化学稳定性的影响"", 《沈阳药科大学学报》 * |
| 胡英杰等: ""羟氨苄青霉素可溶性粉的稳定性研究"", 《中国兽药杂志》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105919941A (en) * | 2016-05-17 | 2016-09-07 | 湖南泰谷生物兽药有限公司 | Composition containing amoxicillin and potassium clavulanate, and preparation method thereof |
| CN106366143A (en) * | 2016-08-30 | 2017-02-01 | 河北舒凯生物科技有限公司 | Tylosin lactate compounds, and composition and application thereof |
| CN106509372A (en) * | 2016-10-09 | 2017-03-22 | 杨松杞 | New water-soluble carrier and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105193752B (en) | A kind of vildagliptin tablet and preparation method thereof | |
| CN101836978A (en) | The solid preparation that contains single crystal form | |
| CN101732236A (en) | Solid medicine preparation for preventing agglomeration and discoloration and preparation method thereof | |
| CN103462918A (en) | Valaciclovir hydrochloride tablet and preparation method thereof | |
| CN110037031B (en) | Preparation method of pH/temperature double-sensitive spinosad controlled-release granules | |
| CN102688252A (en) | Acarbose oral solid preparation composition and preparation method thereof | |
| CN103610677A (en) | Repaglinide troche and preparation method thereof | |
| CN106265536B (en) | Bortezomib pharmaceutical composition and preparation method thereof | |
| CN104873501A (en) | Sulbactam sodium composition for treating infectious diseases | |
| EP2379057B1 (en) | Phenylephrine formulations with improved stability | |
| CN113476406A (en) | Veterinary compound amoxicillin powder and preparation process thereof | |
| CN109481412A (en) | A kind of II crystal linezolid piece and its preparation process | |
| CN103462926A (en) | Famciclovir tablet and preparation method thereof | |
| CN106667898A (en) | Decoquinate preparation as well as preparation method and application thereof | |
| CN102743369A (en) | N-acetylcysteine pharmaceutical composition and preparation method thereof | |
| CN106749174B (en) | A kind of sitafloxacin dihydrate crystal form, preparation method and combinations thereof tablet | |
| CN104000774A (en) | Tannin paste and preparation method | |
| CN104146977A (en) | Pantoprazole sodium enteric coated tablet and preparation method thereof | |
| CN107569504B (en) | Ambroxol hydrochloride dispersible tablet and preparation method thereof | |
| CN104173310A (en) | Stable amoxicillin tablet composition, as well as preparation method and application thereof | |
| US10130627B2 (en) | Phenylephrine formulations with improved stability | |
| CN102846624B (en) | Compound telmisartan hydrochlorothiazide pharmaceutical composition and preparation method thereof | |
| CN109730969A (en) | A kind of levofloxacin lactate dispersible tablet and preparation method thereof | |
| CN103494782A (en) | Ganciclovir tablet and preparation method thereof | |
| CN101721416B (en) | Huperzine A solid composition and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20100616 |